Speaker
Description
Amino modified (proline, tryptophan and poly-L-lysine) magnetic nanoparticles were used to design potential theranostic agents for cancer diagnosis and for combined radionuclide and hyperthermia therapy [1]. Detailed characterization of prepared MNPs was performed using of various techniques, such as dynamic light scattering, electron microscopy, magnetization measurements or thermogravimetric analysis. Measurements in an alternating and non-alternating magnetic field were also conducted. For the first time amino acid-functionalized magnetic nanoparticles were labeled with theranostic radionuclides $^{131}$I and $^{177}$Lu. Radiolabeling with $^{131}$I did not provide agents with sufficient radiochemical purity and stability. On the other hand, direct radiolabeling with $^{177}$Lu at room and elevated temperature provided satisfactory results in case of proline and tryptophan modified MNPs. Poly-L-lysine functionalized MNPs obtained by radiolabeling at $80$ °C reached very high radiochemical purity and high in vitro and in vivo stability. Moreover, SAR value obtained for poly-L-lysine functionalized MNPs shows their high potential for the possible hyperthermia application. Biodistribution of radiolabeled functionalized MNPs was studied in healthy male Wistar rats. The results are encouraging for the future research on discovering the full potential of $^{177}$Lu– PLL-MNPs ($80$ °C) for hyperthermia-based cancer treatment in combination with radioactivity.
Acknowledgements
This work was supported by the Slovak Research and Development Agency under the contract no. APVV-DS-FR-22-0037 and Slovak Grant Agency VEGA 02/0049/23.
References
[1] M. Mirković et al., “Design and preparation of proline, tryptophan and poly-l-lysine functionalized magnetic nanoparticles and their radiolabeling with 131I and 177Lu for potential theranostic use,” International Journal of Pharmaceutics, vol. 628. Elsevier BV, p. 122288, Nov. 2022. https://doi.org/10.1016/j.ijpharm.2022.122288
